|
Results of a quality improvement program to increase complete lung cancer biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes
Journal of Clinical Oncology 42, 2024 (suppl 16; abstr e23249) doi.org/10.1200/JCO.2024.42.16_suppl.e23249 Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study Journal of Clinical Oncology 42, 2024 (suppl 16; abstr 6079) ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.6079 Integrating electronic health records (EHRs) to facilitate cancer biomarker testing: Real-world implementation barriers and solutions Journal of Clinical Oncology 42, 2024 (suppl 16; abstr e13649) doi.org/10.1200/JCO.2024.42.16_suppl.e13649
0 Comments
EP12.02-10 Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative
Journal of Thoracic Oncology, Volume 18, Issue 11, S678 doi.org/10.1016/j.jtho.2023.09.1303 EP07.04-22 Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US Journal of Thoracic Oncology, Volume 18, Issue 11, S554 doi.org/10.1016/j.jtho.2023.09.1035 EP07.04 EARLY-STAGE NON-SMALL CELL LUNG CANCER - PROGRESS IN PATHOLOGY| VOLUME 18, ISSUE 11, SUPPLEMENT , S554, NOVEMBER 2023 EP12.02 METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY - FUSIONS| VOLUME 18, ISSUE 11, SUPPLEMENT , S678, NOVEMBER 2023 Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT)
academic.oup.com/ajcp/article/160/Supplement_1/S90/7455442?login=false Poster presented at American Society for Clinical Pathology 2023 Hung Y, Liu X, Nam M, Rosa M, Saeed L, Schulte JJ, Zhang H, Zhang W, Chivukula M, Beumer K, Kelly M, Kim J, Lazure P, Murray S. Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT). Am J Clin Pathol. 2023;160(Supplement_1):S90. Results of a quality improvement program to increase complete lung cancer biomarker testing rates.
ascopubs.org/doi/10.1200/OP.2023.19.11_suppl.57 Poster presented at ASCO Quality Care Symposium 2023 Heron DE, Blair J, Francis JE, Stoeppler-Biege K, Simpson L, Stapp J, Kim J. Results of a quality improvement program to increase complete lung cancer biomarker testing rates. JCO Oncol Pract. 2023;19(11_suppl):57-57. Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT)
American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Page S90 doi.org/10.1093/ajcp/aqad150.199 Disseminating Education about HER2-Low Breast Cancer through Twitter Chats and Tweetorials American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Pages S97–S98 doi.org/10.1093/ajcp/aqad150.215 Challenges in Testing Across the HER2+ Breast Cancer Spectrum
This CME/CMLE-accredited, case-based microlearning activity from ASCP is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum. Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to help you make an appropriate diagnosis/recommendation. Visit ASCP’s Qstream site at ascp.qstream.com/ Sign up for a Qstream account. Enroll in the case-based microlearning series "Challenges in Testing Across the HER2+ Breast Cancer Spectrum."  Clinical Education Alliance (CCO, PCE, ProCE), in partnership with Q Synthesis LLC, invites outpatient medical practices in the United States to apply to join a national quality improvement (QI) program on obesity care.
pages.mycea.com/EVT_2023-Jan-Obesity_Change_Makers.html Empowering pathologists to lead immuno-oncology (IO) biomarker testing in the community
Journal of Clinical Oncology doi.org/10.1200/JCO.2022.40.28_suppl.348 Leveraging continuing education and implementation science approaches to improve the care of patients with myeloproliferative neoplasms Journal of Clinical Oncology doi.org/10.1200/JCO.2022.40.28_suppl.334 Reducing preventable ED visits in patients with advanced NSCLC: Collective insights from three cancer centers Journal of Clinical Oncology doi.org/10.1200/JCO.2022.40.28_suppl.337 A mixed-methods study to identify key priorities around improving team-based care coordination for patients receiving combination IV and oral systemic anti-cancer therapy Journal of Clinical Oncology doi.org/10.1200/JCO.2022.40.28_suppl.052 Association of Community Cancer Centers key quality care recommendations for stage IB to IIIA non–small cell lung cancer Journal of Clinical Oncology doi.org/10.1200/JCO.2022.40.28_suppl.030 Don't miss this CME Tweetorial (also known as a "threaded tweet") on #HER2LOW breast cancer!
twitter.com/ASCP_Chicago/status/1565009200106946563 View other HER2 breast cancer resources here: www.ascp.org/content/learning/breast-cancer#HER2-low |
